Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis

Authors: Xing, Zhou; Charters, Thomas James

Source: Expert Review of Vaccines, Volume 6, Number 4, August 2007 , pp. 539-546(8)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

The current tuberculosis (TB) epidemic continues to call for the development of effective vaccination strategies. The initial TB vaccine research effort mostly focused on the search for a vaccine that might be better than, and thus could replace, the current bacillus Calmette-Guérin (BCG) vaccine. It has increasingly been realized that BCG or an improved BCG will continue to be used as a prime TB vaccine and there is a need to develop effective boost vaccines that could enhance and prolong the protective immunity of BCG prime immunization. Mounting experimental evidence suggests that recombinant vaccines, including both recombinant protein and genetic vector vaccines, are effective in boosting immune activation and protection by BCG vaccination. This review will discuss recent advances and the authors' views in the development of there boost vaccines.

Keywords: BCG; mucosal immunization; prime-boost; tuberculosis; vaccines; viral vector

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14760584.6.4.539

Publication date: 2007-08-01

More about this publication?

Expert Review of Vaccines provides expert reviews on the clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines in bioterrorism.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites